An overnight assay, based on staining cytomegalovirus-infected cells with monoclonal antibody to the 72,000-molecular-weight major immediate-early viral protein, was compared with a conventional 14-day plaque assay for quantitation of cell-free stocks of cytomegalovirus laboratory strain AD-169 and 20 other clinical strains. Viral titers were quantitatively similar when determined by either method, but centrifugation of monolayers during inoculation enhanced viral infectivity an average of 4.1-fold. When used for scoring neutralizing antibody assays, monoclonal antibody staining yielded titers within one dilution of 14-day plaque-reduction assays in 54 of 56 titrations. Of 21 cytomegalovirus strains, 2 were not recognized by the monoclonal antibody used. Assay with monoclonal antibody offers a rapid and accurate alternative to plaque assays for quantitation or neutralization of cytomegalovirus.
Efforts have been made to replace traditional tissue culture methods for detection and quantitation of cytomegalovirus (CMV) with more rapid yet reliable methods based on newly available reagents such as DNA probes or monoclonal antibodies. Rapid methods have become increasingly important because of the possibility of antiviral therapy for CMV disease. Quantitation of CMV is essential for assessing the impact of therapy on viral shedding and for assay of neutralizing antibody in sera.
Several years ago we reported a method for quantitating CMV in urine specimens by DNA hybridization, in which the intensity of the hybridization signal correlated with the tissue culture infective titer (6) . The subsequent availability of monoclonal antibodies to the 72,000-molecular-weight (72K) major immediate-early (IE) protein of CMV provided an alternative means of rapid identification of CMV-infected cells, and a number of studies have demonstrated the possibility of detecting CMV in specimens 1 to 2 days after inoculation into tissue culture (9, 12, 14, 16, 24) . In some comparison studies, the number of CMV-positive urine specimens detected by monoclonal antibody staining was greater than that detected by traditional techniques (1, 10) . However, variations in technique, such as centrifuge-assisted viral absorption, could have accounted for these differences in sensitivity, independent of the use of monoclonal antibody.
Because of the potential usefulness of monoclonal antibodies for rapid determination of CMV titer, we have studied the quantitative performance of traditional plaque assays (26) in comparison with that of an overnight assay with a recently developed IE monoclonal antibody. We also determined neutralization endpoints of various immune sera against CMV, comparing the traditional plaque reduction assay (17, 20) with one scored with monoclonal antibody after overnight incubation. We used a wide variety of strains of CMV to assess the general applicability of the rapid methods and the potential impact of strain variation on detectability by a single monoclonal antibody. (26) . The inoculum was removed and replaced with a 1-ml overlay of Eagle minimal essential medium containing 0.6% agar and 10% calf serum. After 1 week another 1 ml of the same overlay was added. At the end of the 2-week period (10 days for strain AD-169), the overlay was removed, the monolayer was fixed in methanol, viral plaques were stained with 0.03% methylene blue for 20 min, and the number of plaques per well was counted under an inverted microscope. Quantitation was based on plaque counts in the dilution giving about 200 plaques per well.
Rapid scoring of virus titrations was performed by using mouse monoclonal antibody L-14 (fast protein liquid chromatography purified; Johnson & Johnson Biotechnology Center, La Jolla, Calif.), which is specific for the 72K major IE protein of CMV (21) . Plates to be evaluated were incubated for 20 h at 37°C after virus absorption in regular culture medium (no agar). Monolayers were then washed once with sucrose-phosphate (SP) buffer (16 mM sodium phosphate, 2 mM potassium phosphate, 2% sucrose, pH 7.8) and fixed in methanol. After monolayers were washed twice in SP buffer, they were "blocked" for 20 min in 0.5 ml of 5% nonfat dry milk to reduce nonspecific binding of antibody and then washed once with SP buffer. Antibody L-14 (4 p.g/ml in SP buffer) was added (0.1 ml per well). The plate was incubated at 37°C for 15 min with continuous rocking to distribute the reagent evenly. After two washes with SP buffer, bound monoclonal antibody was visualized by sequential incubation with biotinylated antimouse antibody (1:100 dilution) and an avidin-peroxidase complex (Vectastain ABC mouse kit; Vector Labs, Burlingame, Calif.), according to directions provided with the commercial kit. Aminoethylcarbazole substrate (200 ,ug/ml in 50 mM sodium acetate buffer, pH 5.5) was used as the peroxidase substrate. Cells positive for CMV revealed dark red nuclear staining 2 to 10 min after substrate addition. Quantitation was based on counts of stained nuclei in the dilution giving about 200 positive cells per well.
Neutralization assay. Neutralization titers of immune sera were determined by incubating serial twofold dilutions of heat-inactivated serum (56°C for 30 min, 0.2 ml of each dilution) with 0.2 ml of virus stock dilution, each containing approximately 800 PFU (20) . Virus dilutions were made in serum-free Eagle minimal essential medium with guinea pig complement (sterile filtered; GIBCO) added to make a concentration of 10%. Serum dilutions were made in Eagle minimal essential medium containing 100 ,ug of amikacin per ml. Serum-virus mixtures were incubated at 37°C for 1 h, and 0.2 ml of each mixture was then used as a viral inoculum for quantitation of infectivity as described above. Neutralization titers were obtained either at 10 to 14 days by the traditional plaque reduction method (17, 20) or at 1 day when plates were scored with monoclonal antibody. Neutralization endpoints were those serum dilutions giving a 60% reduction in counts of plaques or infected nuclei compared with counts for a no-serum control (20) . To improve reproducibility, we required that control counts be in the range of 100 to 600.
ELISA. Immunoglobulin G anti-CMV antibody titers were determined with an ELISA as described previously (8) , except that strain AD-169 antigen of our own preparation was used (5). Serum dilutions were started at 1:1,000, and serial twofold dilutions were tested out to the endpoint. Titers were determined in parallel with neutralization titers on some sera.
RESULTS
Viral quantitation. Technical factors affected the apparent titer of individual CMV stocks. Fibroblast monolayers not at the specified stage of growth tended to give lower virus yields. Centrifugation during absorption increased plaque counts greatly. Overall, with 23 CMV stocks representing 19 distinct strains, we found that the viral titer (PFU per milliliter) as determined by the traditional plaque assay was enhanced an average of 4.1-fold (range, 1.8-to 8.9-fold) by absorption with centrifugation for 20 min at room temperature compared with absorption in an incubator for 1 h. A similar effect was noted when titers were determined by monoclonal antibody staining. Thus, the enhancement of infectivity observed with centrifugation is independent of the scoring method used. The degree of enhancement (1.8-to 8.9-fold) did not appear to be dependent on the viral strain; other factors such as state of growth of fibroblast monolayers and in vitro adaptation of CMV strains were probably more important. All subsequent experiments described below were performed with centrifuge-assisted absorption.
Traditional plaque assays were used to determine the titers of 31 CMV stocks (19 strains) in comparison with titers in an overnight assay by monoclonal antibody staining of parallel monolayers inoculated similarly. Figure 1 shows the correlation of the infectivity titers as determined by the two methods. Neither scoring method was consistently more sensitive in detecting infectious CMV. This was seen throughout the range of viral titers, ranging from 102 to 107 PFU/ml. Most clinical strain stocks had titers in the range of 104 PFU/ml, whereas laboratory strain AD-169 was readily propagated to a titer of 107 PFU/ml.
Each assay method was occasionally problematic. As is widely known, some clinical strain stocks do not plaque well on the traditional assay; plaques were sometimes too small or poorly formed, at least at 14 days postinoculation. Further propagation of the strain was then required to obtain stocks which formed better plaques. Serial propagation was not necessary for antibody staining. However, among the 21 CMV strains studied, 2 were stained weakly or not at all by antibody L-14, despite attempts to stain at various intervals from 0.5 to 7 days postinoculation with stocks and inocula 7. However, when the titers differed, there was a te the rapid assay to give a slightly higher titer. W that this may be due to partial inhibition of the ir diluted neutralizing antibody, causing a delay in ance of IE antigen, which would affect the over but not the 2-week reading. Nevertheless, this eff to be a minor one.
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